Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.
Drilling down on obesity drugs: What medtech executives are saying Read More »
Ichnos Sciences Inc. today announced dosing of the first patient in the Phase 1 first-in-human clinical trial of ISB 2001, a BCMA x CD38 x CD3 TREAT™ trispecific antibody1, for the treatment of multiple myeloma.
ICHNOS SCIENCES ANNOUNCES INITIATION OF FIRST-IN-HUMAN CLINICAL TRIAL FOR ISB 2001 Read More »
Cencora, Inc., formerly AmerisourceBergen Corporation, reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion.
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results Read More »
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results Read More »
KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, taking place in Anaheim, CA from November 9-13.
Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, announced it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.
Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit Read More »
BD, a leading global medical technology company, launched new needle-free blood draw technology compatible with integrated catheters, helping to further enable the company’s vision of a “One-Stick Hospital Stay.”
En la era digital actual, los mundos virtuales se han convertido en un fenómeno fascinante que trasciende la mera diversión en línea. Estos entornos digitales, como Second Life y sus contemporáneos, ofrecen a los usuarios la oportunidad de crear, interactuar y vivir exper …
Explorando mundos virtuales: Más allá de la realidad con Second Life y sus pares Read More »
The MODIA® study didn’t meet the primary end-points, but showed high rates of treatment response in both study arms, with no adverse events associated with the use of MODIA.
AlzeCure Pharma AB announced that the company is participating at Redeye Life Science Day 2023 on November 23 at 11:30 CET, where CEO Martin Jönsson will present and answer questions about the latest developments and the company’s plans going forward.
AlzeCure Presents at Redeye Life Science Day on November 23 Read More »
